Biotronik today released long-term data from registry studies of its Linox and Linoxsmart implantable cardioverter defibrillator leads, touting the survival probabilities of over 95% at 4 and 5 years.
The company said its Galaxy and Celestial registry studies include data from a total of 3,933 Linox ICD leads implanted in 3,840 patients across 146 U.S. study centers.
“The results of this large scale, prospective analysis should provide assurance to both implanting physicians and their patients that the magnitude of scientific evidence shows these leads to be safe and reliable.
